NeOnc Secures Second UAE IND for NEO100, Eyes July Phase 2a Results
NTHI•NeOnc Technologies secured its second UAE Investigational New Drug authorization this month, granting IND status for its lead intranasal NEO100 therapy across three clinical protocols, including a pediatric development pathway. The company expects topline Phase 2a results by the end of July and insiders purchased over $500,000 of stock recently.
1. Regulatory Approvals Expand UAE Footprint
NeOnc has secured its second Investigational New Drug authorization from the Department of Health – Abu Dhabi for its lead intranasal candidate NEO100, covering three separate clinical protocols across adult Phase 1 through Phase 2 studies and a pediatric development pathway. This follows an earlier June IND approval for its NEO212 program, rapidly expanding the company’s international regulatory footprint and patient recruitment opportunities in the UAE.
2. Upcoming Clinical Catalyst: Phase 2a Data
The company’s fully enrolled NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is set to report topline results by late July, marking a key data readout for one of the most challenging brain cancer therapies. Strong results could support discussions with regulators for Breakthrough Therapy designation and other expedited pathways.
3. Insider Buying and Financial Position
Chairman and CEO Amir Heshmatpour invested more than $500,000 in open-market purchases recently, bringing total insider buying to nearly $1 million over the past year. NeOnc also holds a $75 million at-the-market facility and a $10 million line of credit, providing capital to advance its CNS oncology pipeline.
